The federal government’s recent move to reclassify certain state-licensed medical cannabis products from Schedule I to Schedule III represents one of the most significant federal cannabis policy shifts in decades. For the first time, the federal government is formally recognizing that state-regulated medical cannabis programs have a legitimate medical framework and should not be treated the same as substances deemed to have no accepted medical use. The Department of Justice has stated that FDA-approved marijuana products and marijuana products subject to qualifying state-issued medical cannabis licenses will be placed in Schedule III, while DEA proceedings on broader marijuana rescheduling are expected to begin on June 29, 2026.
For the cannabis industry, this is progress. But it is not federal legalization. It is not full descheduling. And it does not immediately solve the core challenges facing adult-use operators, multi-state operators, investors, lenders, landlords, insurers, or consumers.
What changed?
The order applies to state-licensed medical cannabis and FDA-approved cannabis-derived medicines. That means qualifying medical cannabis operators may be able to move out from under Schedule I treatment and into Schedule III treatment, which carries lower federal restrictions. According to reporting from Reuters and AP, the change is expected to reduce research barriers, improve the tax treatment of qualifying medical cannabis businesses, and create an expedited DEA registration path for certain state-licensed medical operators.
The most immediate business implication is tax-related. Under Schedule I, cannabis operators have been subject to Internal Revenue Code Section 280E, which prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Moving qualifying medical cannabis products to Schedule III could allow eligible operators to deduct ordinary and necessary business expenses, significantly improving cash flow, EBITDA, reinvestment capacity, and valuation.
However, the relief is not industry-wide. Adult-use cannabis remains federally illegal, and marijuana products not distributed through a qualifying state medical marijuana program remain in Schedule I.
Why this matters for operators today
For medical cannabis operators, this creates a potential inflection point. Businesses that have been operating under intense federal tax pressure may now have a path toward improved profitability and stronger balance sheets. That could change how investors view licensed medical assets, how operators model future cash flow, and how buyers value dispensaries, cultivation facilities, processors, and vertically integrated businesses.
This could also increase institutional interest in the sector. Schedule III status may make cannabis more attractive to certain lenders, strategic buyers, and investors who have historically avoided the space due to federal illegality, tax inefficiency, and enforcement uncertainty. Reuters reported that legal U.S. cannabis sales are expected to exceed $47 billion in 2026, underscoring the size of the opportunity if federal policy continues to evolve.
But operators should avoid treating this as an automatic windfall. The details matter. Eligibility, DEA registration, state license structure, revenue segmentation, accounting treatment, tax positions, and compliance controls will all become more important.
The challenges ahead
The first challenge is scope. The current order is focused on medical cannabis, not the entire cannabis industry. Business of Cannabis noted that only a portion of active cannabis licenses are medical-only, while many operators participate in adult-use markets or hold both medical and recreational licenses. That raises unresolved questions about how companies should separate medical and adult-use revenue, expenses, inventory, tax treatment, and compliance obligations.
The second challenge is compliance. Schedule III does not mean unregulated. In fact, it may bring greater scrutiny. Medical operators seeking federal protection may need to demonstrate that they are operating within a legitimate medical framework, maintaining appropriate records, preventing diversion, and complying with DEA expectations. Business of Cannabis highlighted concerns that federal recognition of state medical programs may also bring federal audit and enforcement expectations, particularly around high-volume medical certifications, telehealth recommendations, and whether sales are genuinely medical in nature.
The third challenge is timing. Operators may face important deadlines tied to DEA registration and expedited review. Business of Cannabis reported that operators filing within 60 days of Federal Register publication may qualify for an expedited review process and may be able to continue operating under existing state licenses while applications are pending.
The fourth challenge is litigation and politics. Opponents of cannabis reform are expected to challenge the order and broader rescheduling efforts. Business of Cannabis reported that legal challenges may focus on the administrative process, the treaty pathway used for the medical cannabis order, and whether the government has built a sufficient evidentiary record.
What happens next?
The next major milestone is the DEA administrative hearing scheduled to begin June 29, 2026. The DOJ has stated that this hearing will address the proposed rescheduling of marijuana more broadly.
This is where the adult-use industry will be watching closely. The current order does not legalize recreational cannabis and does not move adult-use cannabis into Schedule III. Reuters reported that Acting Attorney General Todd Blanche indicated the government would fast-track a broader effort to reclassify marijuana, but that broader process still needs to play out.
For adult-use operators, the likely near-term reality is continued uncertainty. They may not receive immediate 280E relief. They may continue facing banking limitations, capital constraints, interstate commerce restrictions, and federal illegality. Even if the federal government eventually expands rescheduling, adult-use cannabis could face a more complex administrative process and potential litigation.s.
What does this mean for recreational cannabis?
Recreational cannabis remains in a gray but familiar position: legal in many states, illegal federally. The federal government’s action validates the medical side of the market, but it does not fully resolve the disconnect between state legalization and federal prohibition.
This could create a temporary two-tier market. Medical cannabis operators may gain tax and regulatory advantages that adult-use operators do not receive. Vertically integrated MSOs with both medical and adult-use operations may need to carefully analyze how revenue is categorized and how costs are allocated. Standalone adult-use businesses may find themselves at a disadvantage until broader rescheduling or descheduling occurs.
This could also influence state policy. Some states may revisit medical cannabis frameworks to ensure operators can qualify for federal protections. Others may strengthen patient certification rules, seed-to-sale tracking, recordkeeping, product testing, and diversion controls to align with federal expectations.
Is Schedule III the best outcome for the industry?
Schedule III is a major improvement over Schedule I, but it is not the ideal long-term solution for the cannabis industry.
From a practical business perspective, Schedule III may be the most achievable near-term federal reform. It provides meaningful tax relief for qualifying medical operators, reduces research barriers, and gives the industry a stronger legal foundation. It may also help shift public, investor, and institutional perception by formally recognizing cannabis as having accepted medical use.
However, Schedule III still keeps cannabis within the Controlled Substances Act. It does not create a national adult-use market. It does not solve interstate commerce. It does not automatically normalize banking. It does not eliminate state-by-state fragmentation. It does not fully protect recreational operators. And it may introduce new DEA-related compliance requirements for medical cannabis businesses.
For many operators, the best long-term outcome would be federal descheduling paired with a responsible regulatory framework that addresses product safety, age restrictions, testing, labeling, interstate commerce, taxation, social equity, research, and consumer protection. But in the current political environment, Schedule III may be the most realistic bridge between prohibition and broader reform.
What operators should do now
VCannabis businesses should not wait for the dust to settle. The operators that benefit most from this shift will be the ones that prepare early.
Medical operators should evaluate DEA registration requirements, review whether their state license qualifies, strengthen compliance documentation, and work with tax professionals to assess 280E implications. Operators with both medical and adult-use revenue should begin building defensible revenue segmentation and cost allocation models. Investors and buyers should revisit valuation assumptions, especially for medical assets where improved tax treatment could materially impact cash flow.
Adult-use operators should monitor the June 29 DEA proceedings, assess downside scenarios, and avoid assuming immediate federal tax relief. They should continue focusing on operational discipline, margin protection, compliance controls, local licensing strength, and defensible market positioning.
Arcview Consulting’s perspective
This is a meaningful step forward, but it is not a victory lap. The federal government has opened the door for medical cannabis to be treated differently, but the industry still faces legal, operational, financial, and compliance complexity.
For operators, investors, and sellers, the key question is no longer simply whether cannabis will be rescheduled. The better question is: how will your business be positioned when federal policy changes faster than your internal infrastructure?
Arcview Consulting helps cannabis operators, brands, investors, and license holders navigate licensing strategy, compliance readiness, financial modeling, investor positioning, valuation, and transaction advisory. As the federal landscape evolves, operators that can demonstrate strong documentation, compliant operations, defensible financials, and a clear strategic plan will be better positioned to attract capital, pursue expansion, and maximize enterprise value.